reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a PRESS RELEASE reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage...

reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program Press Release reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program Leuven Belgium, 4 November 2021: reMYND NV, a clinical stage company...

reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase Press release reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase Leuven Belgium, 21 October 2021: reMYND...

reMYND extends Series B funding to EUR 24 million Press Release reMYND extends Series B funding to EUR 24 million Financing enables advancement of key programs in Alzheimer’s and Diabetes through Clinical Proof of Concept in 2022Additional EUR 12...

reMYND commences first-in-human trial of ReS19-T Alzheimer’s program Press Release reMYND commences first-in-human trial of ReS19-T Alzheimer’s program RES19-T represents a novel approach to treat Alzheimer’s at the root of the disease and restore cognition Board...